Get to Know… Irene Ghobrial, MD January 3, 2024 - Dr. Ghobrial, of the Dana-Farber Cancer Institute, discusses how she entered the field of smoldering myeloma, the PCROWD and PROMISE studies, and the racial gap in myeloma research, treatment, and diagnosis.
Study sheds light on precancerous ‘clonal outgrowth’ in blood cells September 26, 2022 - A common spontaneous mutation in blood stem cells – which has been linked to higher risks of blood cancer and cardiovascular disease – may promote these diseases by altering the stem cells’ programming of gene activity and the mix of blood cells they produce, according to a study co-led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center, Harvard Medical School and Dana-Farber Cancer Institute.
Dana-Farber’s Irene Ghobrial, MD, Selected as William Dameshek Prize Winner August 10, 2022 - Irene Ghobrial, MD, Director of the Clinical Investigator Research Program at Dana-Farber Cancer Institute, Boston, has received the William Dameshek Prize. This award is given annually by the American Society of Hematology (ASH) to an individual younger than age 50 who has made outstanding contributions in hematology.
MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma December 14, 2020 - The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) — a precursor condition to multiple myeloma.
Katie Couric Helps Spread the Word About Why Blood Cancer is Often Diagnosed Too Late November 27, 2020 - In a recent interview, Katie asked our study's principal investigator, Irene Ghobrial, MD, to help readers understand why blood cancers are often diagnosed too late. Most of us, even people with risk factors for blood cancers such as Multiple Myeloma, Lymphoma, and Waldenström Macroglobulinemia may not ever be screened until they have symptoms.
Irene Ghobrial, MD receives SU2C Catalyst grant November 21, 2017 - Irene Ghobrial, MD, co-director of the Center for Prevention of Progression of Blood Cancers, is among the first to receive a research grant through the Stand Up To Cancer (SU2C) Catalyst program.
We walked the 2017 Jimmy Fund Walk On September 24, the Center for Prevention of Progression of Blood Cancers' PCROWD study nine- member team walked the 2017 Jimmy Fund Walk to raise funds for the PCROWD study. We raised more than $5000 that will go to fund our research of precursor conditions. To see photos of the event, click here.
We climbed Kilimanjaro! July 2017 - Alex Detappe, MSc and Irene Ghobrial, MD climbed mount Kilimanjaro to raise funds for the Leukemia and Lymphoma Society.
Key highlights from the ESH Clinical Updates meeting on Multiple Myeloma May 22, 2017 - Irene Ghobrial from the Dana-Farber Cancer Institute proposed that in this respect the unique property of MM, in having a well-characterized precursor state, should be taken advantage of. A program in which patients were ‘empowered’ to send samples themselves that could be used to screen for possible prognostic factors for progression from MGUS to MM, was outlined.
2016 ASH Abstract Achievement Award Recipients Five Ghobrial Lab team members, Jihye Park, PhD, Yujia Shen, PhD, Salomon Manier, MD, Karma Salem, MD, and Juliette Bouyssou, were recognized with the 2016 ASH Abstract Achievement Award
The genomics behind blood cancers and other blood disorders September, 2016 - Many of the secrets of why precancerous conditions sometimes become cancerous are hidden in cells’ genes. At Dana-Farber, researchers are collecting tissue samples to see if they can pry open those secrets and unlock new treatment options for certain types of blood cancers and other blood disorders.
How can we improve our understanding of the progression of myeloma? June, 2016 - Irene Ghobrial, MD of the Dana-Farber Cancer Institute (DFCI), Boston, MA, discusses the progression of multiple myeloma (MM), which comes from precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. It is not known, however, which patients will progress.
Treatment is Waiting In 2014, Ghobrial launched Dana-Farber’s new Center for Prevention of Progression of Blood Cancers, which sees patients with early myelodysplastic syndromes (MDS), early CLL, monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma, which can progress to multiple myeloma, in order to learn more about the natural history of these cancers and develop therapies that could potentially prevent progression.
Gift funds precursor condition research for blood cancers Spring 2016 - A generous gift from anonymous donors may give new hope to those diagnosed with “precursor conditions,” conditions that, although not yet cancerous, may develop into blood cancers including leukemia, lymphoma, or myeloma. Impact, Volume 19, Issue 2.
Irene Ghobrial, MD explains Dana-Farber's CPOP January 15, 2016 - Irene Ghobrial, MD, explains the strategy and need for Dana-Farber’s Center for the Prevention of Progression of Blood Cancers -- a research initiative focused on understanding the progression and evolution of blood cancers, with an aim to develop targeted medicines that will leading to early interventions that can eliminate blood cancers.
Center for Prevention of Progression of Blood Cancers The Center for Prevention of Progression of Blood Cancers at Dana-Farber Cancer Institute, under the direction of Irene Ghobrial, MD, is the first in the nation - leading research and clinical efforts to halt the progression of precancerous conditions before they develop into blood cancers.
Irene Ghobrial, MD, International Myeloma Foundation 2016 Senior Grant Award recipient Irene Ghobrial, MD, from Dana-Farber Cancer Institute, has been awarded the Brian D. Novis Senior Grant to continue her work in blood biomarkers for clonal progression in multiple myeloma.
Irene Ghobrial, MD, was invited to participate in a panel of Clinical Investigators at ASH 2015 Clinical Investigators provided their perspectives on challenging issues and ongoing research in the management of multiple myeloma. Five general hematologic oncologists identified patient scenarios, management concerns, and available data sets that pose the greatest challenge to their clinical decision making. Utilizing this information as the basis for the agenda, the distinguished panel of myeloma experts employed didactic presentations, audience polling featuring networked table devices, and panel discussion that provided perspectives on new and emerging research and addressed the real-world concerns voiced by the group.
Aldo Roccaro New Young ISSNAF Co-Coordinator Aldo Roccaro,MD, PhD, senior scientist at Harvard, will be Young ISSNAF's Co-Coordinator. Aldo is the recipient of the 2015 Paola Campese Award on Research on Leukemia and had a special mention in 2013 for the same Award.
Irene Ghobrial, MD, invited speaker at MHM, discusses how she treats smoldering myeloma September 18, 2015 - Dr. Irene Ghobrial will reviews 1) the current knowledge of smoldering myeloma and risk factors associated with progression, as well as biological insights and alterations that occur in the tumor clone and the surrounding bone marrow niche, 2) clinical trials that have been performed in these patients and 3) recommendations for follow-up of patients with this unique disease entity.
Keeping cells from supporting tumors Summer 2015 - Dr. Ghobrial and other scientists are exploring different aspects of the tumor microenvironment – the molecules, cells, and blood vessels that surround and support a tumor.
Myeloma Survival Blogpost February 17, 2015 - "Dr. Irene Ghobrial of the Dana Farber Cancer Institute was on the Feb 12th Cure Panel and her broadcast was exceptional, however I want to talk of one MAJOR takeaway I had from the program. Her point was simple, straight forward, logical, and impossible to argue against that Multiple Myeloma is the only cancer where we wait for it to metastasize and show organ, bone damage, or anemia before we begin treatment."
Curetalks Broadcast: Early treatment of Myeloma with Dr. Irene Ghobrial Listen to Dr. Ghobrial as she discusses new strategies to help MGUS and smoldering patients. In contrast to the watch and wait approach practiced by doctors for patients where disease progression is not easily discernible, this new approach to understand the patients' condition and treat early may prove to be life saving. Curetalks site and blogtalkradio site
Irene Ghobrial Receives Mentoring Award This year's postdoc and graduate student retreat concluded with the announcement that Irene Ghobrial, MD, of Medical Oncology is the recipient of the 2014 Mentor of the Year Award. In announcing the award, Chief Scientific Officer Barrett Rollins, MD, PhD, recalled that when Ghobrial arrived at the Institute, "she was incredibly hungry to begin her research into B cell malignancies," and she brings the same energy to working with students in her lab. "When her fellows and postdocs give research presentations, she knows how to ask the right questions, she knows how to be supportive, and knows how to draw out her mentees."
Saint Francis Partners With Dana-Farber For Clinical Trials October 24, 2014The relationship with Saint Francis starts immediately, building on other relationships that were started with other hospitals two years ago, said Dr. Irene Ghobrial, a medical oncologist and co-director of the Blood Cancer Research Program.
Scientists Engineer Nanoparticles to Prevent Bone Cancer, Strengthen Bones June 30, 2014 - A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH) and has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent bone cancer progression. Read the PNAS full article here.
Blood Cancer Research Project (BCRP) Blood Cancer Research Partnership’s (BCRP) mission is to provide innovative clinical trials to patients closer to their home. BCRP’s main objective is to bring the novel trials to the patients across the country. Blood Cancer Prevention of Progression Clinic (BCPC) The Blood Cancer Prevention of Progression Clinic (BCPC) is a research initiative focused on understanding the progression and clonal evolution of blood cancers, with an ultimate aim to develop targeted therapeutic agents that can eliminate the early clones of disease.